TCDA - TCDA STOCK NEWS

Tricida, Inc. (Nasdaq: TCDA) will present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 10:30 AM PT. The presentation will include a company overview and updates on key initiatives. A live webcast will be available on the Tricida website, with an archive accessible for 90 days post-presentation.

Tricida specializes in developing veverimer, an investigational drug aimed at slowing chronic kidney disease (CKD) progression in patients with metabolic acidosis. Currently, there are no FDA-approved therapies for this condition affecting approximately 4.3 million CKD patients in the U.S.

Tricida, Inc. (TCDA) announced its financial results for Q4 and the full year of 2021. The company reported a net loss of $50 million for Q4 2021 with a decreased net loss per share of $0.92 compared to $1.09 in Q4 2020. Total net loss for 2021 was $176.6 million. Research & development expenses increased to $36.8 million in Q4 2021, while general & administrative expenses decreased to $9.1 million. The VALOR-CKD trial has completed patient enrollment and is expected to report top-line results in Q4 2022, with sufficient financial resources into Q2 2023.

Tricida, Inc. (Nasdaq: TCDA) will report its fourth quarter and year-end 2021 financial results after the market closes on March 29, 2022. A conference call will be hosted at 4:30 PM Eastern Time to discuss these results and business progress, with access via a dedicated webcast and dial-in options. The company is focused on its investigational drug candidate, veverimer, aimed at slowing chronic kidney disease progression in patients with metabolic acidosis. Currently, there are no FDA-approved therapies for this condition, impacting around three million patients in the U.S.

Tricida, Inc. (TCDA) announced a delay in the expected top-line results from the VALOR-CKD trial due to ongoing disruptions in Ukraine, where 15% of participants are located. Originally slated for Q3 2022, the results are now anticipated in early Q4 2022. The company emphasizes that this delay is necessary to ensure reliable data collection amid the ongoing crisis. As of March 1, 2022, the trial has recorded 197 primary endpoint events, averaging 23 months of treatment. Tricida expects its financial resources to last approximately six months after the top-line results are announced.

Tricida, a pharmaceutical company focused on chronic kidney disease (CKD), will participate in the Kidney Disease / Fibrosis panel at the Cowen 42^nd Annual Health Care Conference. The discussion is scheduled for March 9, 2022, at 11:10 am PT / 2:10 pm ET. The company is developing veverimer, a non-absorbed polymer aimed at slowing CKD progression. Currently, there are no FDA-approved therapies for metabolic acidosis in CKD patients, affecting approximately three million people in the U.S. A live webcast of the panel will be available on Tricida's website.

Toragen Inc., based in San Diego, has announced the appointment of Dr. Sandra Coufal as its new CEO, bringing over 30 years of experience in medicine and biotechnology. Dr. Coufal's previous roles include co-founding Sibling Capital and serving on the Management Board of Tricida, Inc. (NASDAQ: TCDA). As the company prepares to submit an Investigational New Drug application to the FDA for its first clinical trial targeting cancers associated with human papillomavirus (HPV), Dr. Coufal aims to enhance drug selectivity and patient tolerance compared to traditional therapies.

Tricida, Inc. (Nasdaq: TCDA) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 7:30 am PT. Gerrit Klaerner, Ph.D., will provide a business update and overview. A live webcast will be available on the Tricida website and archived for 30 days. Additionally, Tricida will present at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10, 2022, at 4:00 am PT, with a recording accessible for 90 days. The company focuses on developing veverimer, a treatment for chronic kidney disease (CKD) progression.

Tricida, Inc. (Nasdaq: TCDA) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 10:30 am PT. Gerrit Klaerner, Ph.D., President and CEO, will discuss the company's overview, business updates, and key initiatives. The presentation will be available via a live webcast on the Tricida website, with an archive accessible for 30 days post-event.

Tricida focuses on developing veverimer, a drug aimed at slowing chronic kidney disease (CKD) progression. This condition affects approximately three million patients in the U.S., with no current FDA-approved therapies targeting metabolic acidosis in CKD.

Tricida, Inc. (TCDA) has secured approximately $42 million in gross proceeds through a registered direct equity financing. Led by Deep Track Capital, the financing includes the sale of 4,666,667 shares at $6.00 per share, pre-funded warrants for 2,333,333 shares, and common warrants for 7 million shares. The financing is expected to close on November 15, 2021. Net proceeds will fund corporate operations, including the VALOR-CKD trial, and extend financial resources into Q1 2023. Key milestones are anticipated for the trial in mid-2022.